| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider activity in ELVN over the last quarter tilts toward selling: insiders offloaded a net 204,849 shares worth roughly $11.8M. In the past 30 days, 0 insiders bought and 3 sold. The bias lately has been to the sell side.
2 of the 3 insiders who sold still hold shares after their sales. Classified under Biotechnology (Health Care sector), ELVN's insider flows are most useful compared with peers in the same group.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 6.56M | $294.98M | - | |
| CEO | 890.4K | $19.43M | - | |
| Dir | 41.9K | $2.13M | - | |
| CFO | 38.0K | $564.3K | -6,018 | |
| Other | 25.0K | $62.0K | -5,000 |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct 19, 2026 | Hohl Benjamin59 | Chief Financial Officer | Sale+OE10b5-1 | 6,018 | $38.48 | $231,545.56 | -13.7% | - | - | |
| Oct 19, 2026 | Collins Helen Louise64 | Chief Medical Officer | Sale+OE10b5-1 | 5,000 | $38.47 | $192,342.00 | -16.7% | - | - | |
| Oct 1, 2026 | Garland J. Scott | Director | Sale+OE | 13,000 | $46.67 | $606,719.10 | - | - | - | |
| Sep 17, 2026 | Hohl Benjamin59 | Chief Financial Officer | Sale+OE10b5-1 | 6,018 | $50.35 | $303,003.01 | -13.7% | - | - | |
| Sep 17, 2026 | Collins Helen Louise64 | Chief Medical Officer | Sale+OE10b5-1 | 5,000 | $50.35 | $251,753.87 | -16.7% | - | - | |
| Aug 17, 2026 | Hohl Benjamin59 | Chief Financial Officer | Sell10b5-1 | 6,018 | $58.58 | $352,551.17 | -13.1% | - | - | |
| Aug 17, 2026 | Collins Helen Louise64 | Chief Medical Officer | Sale+OE10b5-1 | 5,000 | $58.59 | $292,930.78 | -16.7% | - | - | |
| Aug 4, 2026 | Derynck Mika K | Director | Sale+OE10b5-1 | 158,795 | $60.21 | $9,561,586.85 | - | - | - | |
| Jul 17, 2026 | Collins Helen Louise64 | Chief Medical Officer | Sale+OE10b5-1 | 5,000 | $52.67 | $263,373.38 | -16.7% | -26.1% | - | |
| Jul 17, 2026 | Hohl Benjamin59 | Chief Financial Officer | Sale+OE10b5-1 | 6,018 | $52.64 | $316,780.33 | -11.6% | -26.1% | - |